eISSN: 1897-4252
ISSN: 1731-5530
Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
vol. 19
Letter to the Editor

Simultaneous surgical treatment of primary ovarian carcinoid and carcinoid heart disease

Uladzimir Andrushchuk
Aliaxandr Saevich
Viktoria Ermochenko
Mikalai Shchatsinka

Republican Scientific and Practical Centre ‘Cardiology’, Minsk, Belarus
City Clinical Pathologoanatomic Bureau, Minsk, Belarus
University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Southampton, United Kingdom
Kardiochirurgia i Torakochirurgia Polska 2022; 19 (4): 249-252
Online publish date: 2022/12/24
View full text Get citation
PlumX metrics:
The incidence of neuroendocrine tumors (NET) is 2.5–5 per 100 000 population. Up to 20% of patients with NET develop carcinoid syndrome (CS), and in 40–50% of those carcinoid heart disease (CHD) is reported (0.27 per 100 000 population per year) [1]. Development of CS and CHD is determined by numerous vasoactive substances (serotonin, kallikrein, bradykinin, histamine, prostaglandins, etc.) which are produced by NET [2]. Primary ovarian carcinoid is a rare disease and accounts for 0.3–1.0% of all carcinoid tumors and up to 0.1% of ovarian tumors [3]. Venous drainage from ovaries, as from other paired organs, bypasses the liver and enters the vena cava inferior, which is the main reason for early development of CS and manifestation in ovarian carcinoids. Typical clinical symptoms of CS include flushing (90%), diarrhea (70%), wheezing (15%), fatigue, hypotension and arrhythmias [4]. Treatment of CS is a challenge due to often late diagnostics, life-threatening carcinoid crises and lack of established guidelines for surgical treatment of ovarian tumors, associated with CHD [5].
Quick links
© 2023 Termedia Sp. z o.o.
Developed by Bentus.